Antibody targeting of cathepsin S inhibits angiogenesis and synergistically enhances anti-VEGF.
BACKGROUND: Angiogenesis is a key hallmark of tumourigenesis and its inhibition is a proven strategy for the development of novel anti-cancer therapeutics.An important aspect of early angiogenesis is the co-ordinated migration and invasion of endothelial cells through the hypoxic tumour tissue.Cathepsin S has been shown to play an important role in